{"id":"alpha-interferon","safety":{"commonSideEffects":[{"rate":"50-90%","effect":"Flu-like symptoms"},{"rate":"30-70%","effect":"Fatigue"},{"rate":"20-60%","effect":"Headache"},{"rate":"10-40%","effect":"Depression"},{"rate":"10-30%","effect":"Anxiety"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alpha Interferon is a type of cytokine that activates immune cells, such as natural killer cells and T cells, to recognize and destroy infected cells or tumor cells. This leads to the production of other cytokines and the activation of various immune responses.","oneSentence":"Alpha Interferon works by stimulating the body's immune system to fight viral infections and cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:08:18.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic Hepatitis C"},{"name":"Multiple Sclerosis"},{"name":"Hairy Cell Leukemia"},{"name":"Kaposi's Sarcoma"}]},"trialDetails":[{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT02506153","phase":"PHASE3","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-10","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma","enrollment":1301},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT04380545","phase":"PHASE1, PHASE2","title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-13","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8","enrollment":15},{"nctId":"NCT01125228","phase":"","title":"Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1988-10-19","conditions":"HIV","enrollment":180},{"nctId":"NCT00003641","phase":"PHASE3","title":"High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-03-25","conditions":"Melanoma (Skin)","enrollment":1150},{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":"HLA-A2 Positive Cells Present, Refractory Melanoma","enrollment":1},{"nctId":"NCT01274338","phase":"PHASE3","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-25","conditions":"Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7","enrollment":1673},{"nctId":"NCT06716853","phase":"PHASE1, PHASE2","title":"A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Genenta Science","startDate":"2024-10-22","conditions":"Clear Cell RCC","enrollment":10},{"nctId":"NCT03866109","phase":"PHASE1, PHASE2","title":"A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genenta Science","startDate":"2019-03-05","conditions":"Glioblastoma Multiforme","enrollment":27},{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":"Chronic Hepatitis B","enrollment":209},{"nctId":"NCT04379518","phase":"PHASE1, PHASE2","title":"Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2020-11-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":4},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT01708941","phase":"PHASE2","title":"Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-01-18","conditions":"Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7","enrollment":88},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT02201459","phase":"PHASE3","title":"Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-08","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT05970289","phase":"PHASE2","title":"Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2023-08-22","conditions":"Chronic Hepatitis B Virus Infection","enrollment":86},{"nctId":"NCT06545812","phase":"NA","title":"Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Josip Juraj Strossmayer University of Osijek","startDate":"2024-09-02","conditions":"Intervertebral Disc Herniation, Back Pain, Analgesic Nephropathy","enrollment":128},{"nctId":"NCT03899987","phase":"PHASE2","title":"Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2019-11-29","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8","enrollment":12},{"nctId":"NCT00015847","phase":"PHASE2","title":"Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2001-04","conditions":"Leukemia","enrollment":25},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT02533258","phase":"","title":"Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-12-02","conditions":"Renal Cell Carcinoma","enrollment":13},{"nctId":"NCT02992704","phase":"PHASE2, PHASE3","title":"Peg-interferon for Inactive Chronic Hepatitis B Carriers","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2016-08","conditions":"Chronic Hepatitis, B Virus, Carrier of Viral Hepatitis Type B","enrollment":90},{"nctId":"NCT06047132","phase":"","title":"PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS","status":"COMPLETED","sponsor":"Universidad Complutense de Madrid","startDate":"2023-10-23","conditions":"Periodontitis, Saliva, Biomarkers","enrollment":100},{"nctId":"NCT05756166","phase":"PHASE1, PHASE2","title":"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-02-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma","enrollment":5},{"nctId":"NCT06125535","phase":"","title":"Biomolecular Phenotyping of Lung Transplant Recipients","status":"COMPLETED","sponsor":"Policlinico Hospital","startDate":"2022-02-01","conditions":"Lung Transplant Failure","enrollment":80},{"nctId":"NCT06650852","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)","status":"RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-10-31","conditions":"Chronic Hepatitis B Virus (HBV) Infection","enrollment":250},{"nctId":"NCT02380443","phase":"PHASE2","title":"AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mirror Biologics, Inc.","startDate":"2016-09","conditions":"Colorectal Cancer Metastatic","enrollment":13},{"nctId":"NCT04418219","phase":"PHASE1, PHASE2","title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2020-12-21","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT06926647","phase":"","title":"A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-05-01","conditions":"HBV, Chronic Hepatitis b","enrollment":2000},{"nctId":"NCT00442572","phase":"PHASE2","title":"SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07-03","conditions":"Hepatitis B, Chronic","enrollment":21},{"nctId":"NCT01194037","phase":"PHASE1, PHASE2","title":"A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2011-06-23","conditions":"Chronic Hepatitis C Infection, Genotype 1","enrollment":30},{"nctId":"NCT04035837","phase":"PHASE4","title":"The Clinical Cure Project of Chronic Hepatitis B in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-05-16","conditions":"Hepatitis B, Chronic","enrollment":30000},{"nctId":"NCT06923280","phase":"NA","title":"Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-05-01","conditions":"Hepatitis B, Chronic","enrollment":30},{"nctId":"NCT06137950","phase":"PHASE1","title":"Interferon Alpha Therapy for Cervical CINI and HPV Infection","status":"COMPLETED","sponsor":"Mongolian National University of Medical Sciences","startDate":"2023-11-07","conditions":"Cervical Dysplasia, HPV Infection","enrollment":60},{"nctId":"NCT06827249","phase":"NA","title":"Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2025-03","conditions":"Bronchiolitis","enrollment":90},{"nctId":"NCT01986712","phase":"","title":"A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma","status":"COMPLETED","sponsor":"St. Luke's Hospital and Health Network, Pennsylvania","startDate":"2013-12","conditions":"Melanoma","enrollment":50},{"nctId":"NCT05850273","phase":"","title":"Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2023-03-16","conditions":"Myeloproliferative Neoplasm","enrollment":80},{"nctId":"NCT06802718","phase":"PHASE3","title":"Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-01-01","conditions":"Acute Myeloid Leukemia","enrollment":96},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT06491563","phase":"PHASE2","title":"Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-08-06","conditions":"For Treatment of Chronic Hepatitis B Virus Infection","enrollment":150},{"nctId":"NCT06734637","phase":"NA","title":"Efficacy and Safety of Peginterferon in ET and PV.","status":"RECRUITING","sponsor":"Zhenya Hong","startDate":"2024-11-20","conditions":"Essential Thrombocythemia, Polycythemia Vera","enrollment":40},{"nctId":"NCT00452023","phase":"PHASE2","title":"Pegasys® in Patients With Myeloproliferative Diseases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-04-07","conditions":"Myeloproliferative Disorders","enrollment":83},{"nctId":"NCT06091735","phase":"NA","title":"Clinical Study of Bowel Preparation Before Colonoscopy","status":"COMPLETED","sponsor":"Jinling Hospital, China","startDate":"2023-08-01","conditions":"Bowel Preparation","enrollment":444},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":"Polycythemia Vera","enrollment":586},{"nctId":"NCT04412863","phase":"PHASE2","title":"Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-07-03","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT06582017","phase":"PHASE1","title":"Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma","status":"RECRUITING","sponsor":"Nammi Therapeutics Inc","startDate":"2024-08-28","conditions":"Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma","enrollment":100},{"nctId":"NCT06535048","phase":"","title":"Impact of Fatty Liver on Hepatitis B Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Second People's Hospital","startDate":"2015-01-01","conditions":"Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment","enrollment":500},{"nctId":"NCT05781841","phase":"","title":"Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-04-15","conditions":"Warts","enrollment":100},{"nctId":"NCT06507891","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-06","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT04226950","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-01-10","conditions":"Essential Thrombocytopenia","enrollment":40},{"nctId":"NCT05395507","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-01","conditions":"Essential Thrombocytopenia","enrollment":194},{"nctId":"NCT06222801","phase":"","title":"The 1st Tumor CytokinoTherapy Database (TCTD-1)","status":"RECRUITING","sponsor":"OncoCareClinic 308 Ltd","startDate":"2022-09-19","conditions":"Oncology","enrollment":5000},{"nctId":"NCT04676724","phase":"PHASE2","title":"Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-28","conditions":"Hepatitis B","enrollment":108},{"nctId":"NCT06277167","phase":"PHASE1","title":"A Phase I Study in Healthy Participants","status":"COMPLETED","sponsor":"Kexing Biopharm Co., Ltd.","startDate":"2023-01-07","conditions":"Healthy Participants","enrollment":35},{"nctId":"NCT06371235","phase":"NA","title":"Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier","status":"NOT_YET_RECRUITING","sponsor":"CerbaXpert","startDate":"2024-09","conditions":"Woman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons","enrollment":250},{"nctId":"NCT06356740","phase":"PHASE2","title":"Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-01","conditions":"Systemic Lupus Erythematosus","enrollment":70},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":"Chronic Hepatitis B","enrollment":475},{"nctId":"NCT00695019","phase":"PHASE2","title":"Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C","status":"COMPLETED","sponsor":"Ainos, Inc. (f/k/a Amarillo Biosciences Inc.","startDate":"2009-06","conditions":"Hepatitis C, Chronic","enrollment":169},{"nctId":"NCT04640129","phase":"PHASE4","title":"HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-01-01","conditions":"Liver Fibrosis","enrollment":336},{"nctId":"NCT05065905","phase":"PHASE1, PHASE2","title":"Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2006-01-19","conditions":"HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary","enrollment":78},{"nctId":"NCT00002965","phase":"PHASE2","title":"Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1997-01","conditions":"Brain and Central Nervous System Tumors","enrollment":16},{"nctId":"NCT03638375","phase":"PHASE1, PHASE2","title":"TIL and Anti-PD1 in Metastatic Melanoma","status":"UNKNOWN","sponsor":"Leiden University","startDate":"2018-07-31","conditions":"Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy","enrollment":34},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT01545141","phase":"PHASE1, PHASE2","title":"Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-10","conditions":"Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors","enrollment":15},{"nctId":"NCT04781647","phase":"PHASE2","title":"A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2021-02-18","conditions":"Chronic Hepatitis B","enrollment":54},{"nctId":"NCT04664010","phase":"NA","title":"Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19)","status":"COMPLETED","sponsor":"Xi'an International Medical Center Hospital","startDate":"2020-02-06","conditions":"COVID-19","enrollment":30},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":"Non-Hodgkins Lymphoma","enrollment":27},{"nctId":"NCT04081389","phase":"PHASE1","title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-06","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8","enrollment":9},{"nctId":"NCT04534725","phase":"PHASE3","title":"COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-12-17","conditions":"Cancer, Covid19, Respiratory Viral Infection","enrollment":441},{"nctId":"NCT05729139","phase":"PHASE1","title":"Cemiplimab/Peg-Interferon-α in Advanced CSCC","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2023-07","conditions":"Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03599453","phase":"EARLY_PHASE1","title":"Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-01-09","conditions":"Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative","enrollment":8},{"nctId":"NCT02340962","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2015-05","conditions":"Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT05941845","phase":"PHASE2","title":"Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-07-24","conditions":"Membranous Nephropathy","enrollment":5},{"nctId":"NCT00062010","phase":"PHASE2","title":"Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-05-26","conditions":"Lung Cancer","enrollment":37},{"nctId":"NCT01935089","phase":"PHASE2","title":"Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2013-08-07","conditions":"HIV-1 Infection","enrollment":20},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT00003027","phase":"PHASE3","title":"Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-11-13","conditions":"Melanoma (Skin)","enrollment":482},{"nctId":"NCT00002868","phase":"PHASE3","title":"Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-11-20","conditions":"Leukemia","enrollment":744},{"nctId":"NCT00005847","phase":"PHASE2","title":"Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2001-04-05","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00003444","phase":"PHASE3","title":"Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-03-29","conditions":"Melanoma (Skin)","enrollment":167},{"nctId":"NCT00003266","phase":"PHASE3","title":"Methylphenidate in Treating Patients With Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-10-12","conditions":"Fatigue, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":200},{"nctId":"NCT00054561","phase":"PHASE3","title":"Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2003-11-26","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT00134030","phase":"PHASE3","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-11-14","conditions":"Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1334},{"nctId":"NCT02063464","phase":"","title":"Blood Collection From People With Ovarian Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-10","conditions":"Ovarian Cancer, Cancer of the Ovary, Ovarian Neoplasms","enrollment":85},{"nctId":"NCT05863975","phase":"PHASE4","title":"Treatment of HPV Infection in Perimenopausal and Postmenopausal Women","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-07-01","conditions":"HPV Infection","enrollment":150},{"nctId":"NCT01657604","phase":"PHASE3","title":"TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study","status":"COMPLETED","sponsor":"University of Jena","startDate":"2012-08-24","conditions":"Chronic Myeloid Leukemia","enrollment":717},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT01359956","phase":"PHASE3","title":"Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2002-04","conditions":"Malignant Melanoma, Recurrent Melanoma","enrollment":269},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":"Chronic Myeloid Leukemia in Remission","enrollment":214},{"nctId":"NCT05792878","phase":"","title":"Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2022-09-01","conditions":"Chronic Hepatitis B, COVID-19 Infection","enrollment":600},{"nctId":"NCT04726553","phase":"EARLY_PHASE1","title":"Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE","status":"UNKNOWN","sponsor":"Oklahoma Medical Research Foundation","startDate":"2021-01-20","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":20},{"nctId":"NCT02776644","phase":"","title":"Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-15","conditions":"Renal Cell Carcinoma","enrollment":1349},{"nctId":"NCT04501783","phase":"PHASE3","title":"Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-05-20","conditions":"COVID-19","enrollment":168},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT02430181","phase":"PHASE2","title":"Lonafarnib With and Without Ritonavir in HDV (LOWR-1)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-11","conditions":"Chronic Hepatitis D Infection","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6676,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Alpha Interferon","genericName":"Alpha Interferon","companyName":"Sunnybrook Health Sciences Centre","companyId":"sunnybrook-health-sciences-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alpha Interferon works by stimulating the body's immune system to fight viral infections and cancer. Used for Chronic Hepatitis C, Multiple Sclerosis, Hairy Cell Leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}